Galectin Therapeutics Bolsa (NASDAQ: GALT)

Galectin Therapeutics (NASDAQ:GALT) Bolsa

GALECTIN THERAPEUTICS INC

Galectin Therapeutics

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics Inc

HC Wainwright &amp; Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) from Neutral to Neutral.

News

Reiteration

Analyst Ratings

GALT

HC Wainwright & Co. Reiterates Neutral on Galectin Therapeuticsto Neutral

WIIM

Galectin Therapeutics shares are trading lower following a FY24 EPS miss.

Earnings

Earnings Misses

Galectin Therapeutics FY 2024 GAAP EPS $(0.76) Misses $(0.73) Estimate, Cash Balance Of $15.1M

Galectin Therapeutics shares are trading higher after the company announced results from its NAVIGATE trial.

Biotech

General

Galectin Therapeutics Announces NAVIGATE Trial Results: Belapectin Shows 49.3% Reduction In Varices For Completer Patients In MASH Cirrhosis, Composite Endpoint Not Met

HC Wainwright &amp; Co. analyst Ed Arce downgrades Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) from Buy to Neutral.

Downgrades

HC Wainwright & Co. Downgrades Galectin Therapeutics to Neutral

<h3>Gainers</h3>
<ul>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares rose 114.6% to $1.03 during Friday's pre-market session. The company's market cap stands at $3.8 million. </li>
<li>Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) shares increased by 67.34% to $5.79. The market value of their outstanding shares is at $744.9 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares moved upwards by 62.19% to $3.99. The company's market cap stands at $3.3 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares increased by 37.77% to $0.6. The company's market cap stands at $8.3 million. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) shares rose 29.25% to $30.75. The market value of their outstanding shares is at $162.2 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares rose 16.55% to $3.45. The market value of their outstanding shares is at $3.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) stock declined by 53.1% to $0.16 during Friday's pre-market session. The market value of their outstanding shares is at $1.0 million. </li>
<li>Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) stock decreased by 38.5% to $1.23. The market value of their outstanding shares is at $77.1 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) shares declined by 32.43% to $0.44. The market value of their outstanding shares is at $2.2 million. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) stock decreased by 21.86% to $0.93. The company's market cap stands at $44.9 million. </li>
<li>Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) shares declined by 20.14% to $82.61. The company's market cap stands at $366.9 billion. </li>
<li>Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) shares decreased by 17.71% to $2.51. The company's market cap stands at $10.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AEMD

BCAB

HSDT

HUMA

ISPC

MNPR

MTEM

QNRX

SSKN

12 Health Care Stocks Moving In Friday's Pre-Market Session

U.S. stocks traded higher toward the end of trading, with the Dow Jones index jumping more than 600 points on Friday.
The Dow traded up 1.55% to 43,000.53 while the NASDAQ rose 1.65% to 19,693.06. The S&amp;P 500 also rose, gaining, 1.53% to 5,956.61.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a>
Leading and Lagging Sectors Real estate shares jumped by 2.4% on Friday.
In trading on Friday, consumer staples shares rose by just 0.4%.
Top Headline
The total number of active U.S. oil rigs climbed by 1 to 483 rigs this week, Baker Hughes Inc reported.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Humacyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) shares shot up 40% to $4.8500 after the company announced FDA approval for SYMVESS for treating extremity vascular injuries. HC Wainwright &amp; Co. raised its price target on the stock from $12 to $15.</li>
<li>Shares of Personalis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>)got a boost, surging 25% to $6.55 after the company and Moderna recently announced a multi-year extension to continue utilizing the Personalis ImmunoID NeXT platform and technology for V940/mRNA-4157. The company also announced an investment from Merck.</li>
<li>Taoping Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOP#NASDAQ">TAOP</a>) shares were also up, gaining 37% to $0.4349 after the company announced it received an additional 180 calendar days for compliance with the Nasdaq minimum bid price requirement.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares dropped 74% to $0.4276 as the company reported the pricing of $20.0 million follow on offering.</li>
<li>Shares of Galectin Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) were down 54% to $0.9297 after the company announced top-line results of its NAVIGATE clinical trial and confirmed belapectin did not achieve statistical significance.</li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) was down, falling 17% to $85.72. The company announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE program.</li>
</ul>
Commodities In commodity news, oil traded up 0.1% to $69.43 while gold traded up 1.5% at $2,648.30.
Silver traded up 2.7% to $30.210 on Friday, while copper rose 0.8% to $4.1075.
Euro zone
European shares were lower today. The eurozone's STOXX 600 dipped 0.88%, Germany's DAX fell 0.43% and France's CAC 40 declined 0.27%. Spain's IBEX 35 Index rose 0.24%, while London's FTSE 100 fell 0.26%.
Consumer confidence in the Eurozone declined by 0.8 points to a reading of -14.5 in December.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei 225 falling 0.29%, Hong Kong's Hang Seng Index falling 0.16%, China's Shanghai Composite Index declining 0.06% and India's BSE Sensex falling 1.49%.
Economics
<ul>
<li>The University of Michigan consumer sentiment rose to 74 in December, recording the highest level since April, and versus a reading of 71.8 in November.</li>
<li>U.S. personal income increased by 0.3% month-over-month in November compared to a revised 0.7% gain in October.</li>
<li>Personal spending increased by 0.4% to an annualized rate of $20.2 trillion in November.</li>
<li>The U.S. personal consumption expenditures price index rose 0.1% month-over-month in November down from 0.2% in each of the prior two months and compared to market estimates of 0.2%.</li>
<li>The total number of active U.S. oil rigs climbed by 1 to 483 rigs this week, Baker Hughes Inc reported.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42616304/top-3-risk-off-stocks-that-may-collapse-this-month">Top 3 Risk Off Stocks That May Collapse This Month</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

Markets

PSNL

TAOP

Dow Surges Over 600 Points, Gold Jumps 1.5%

U.S. stocks traded higher midway through trading, with the Nasdaq Composite jumping more than 300 points on Friday.
The Dow traded up 1.82% to 43,111.11 while the NASDAQ rose 1.77% to 19,714.27. The S&amp;P 500 also rose, gaining, 1.76% to 5,970.36.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a>
Leading and Lagging Sectors Real estate shares jumped by 2.6% on Friday.
In trading on Friday, consumer staples shares rose by just 0.6%.
Top Headline
The U.S. personal consumption expenditures price index rose 0.1% month-over-month in November down from 0.2% in each of the prior two months and compared to market estimates of 0.2%.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Humacyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) shares shot up 40% to $4.8500 after the company announced FDA approval for SYMVESS for treating extremity vascular injuries. HC Wainwright &amp; Co. raised its price target on the stock from $12 to $15.</li>
<li>Shares of Personalis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>)got a boost, surging 25% to $6.55 after the company and Moderna recently announced a multi-year extension to continue utilizing the Personalis ImmunoID NeXT platform and technology for V940/mRNA-4157. The company also announced an investment from Merck.</li>
<li>Taoping Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOP#NASDAQ">TAOP</a>) shares were also up, gaining 31% to $0.4153 after the company announced it received an additional 180 calendar days for compliance with the Nasdaq minimum bid price requirement.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares dropped 74% to $0.4173 as the company reported the pricing of $20.0 million follow on offering.</li>
<li>Shares of Galectin Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) were down 53% to $0.9499 after the company announced top-line results of its NAVIGATE clinical trial and confirmed belapectin did not achieve statistical significance.</li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) was down, falling 17% to $86.01. The company announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE program.</li>
</ul>
Commodities In commodity news, oil traded down 0.6% to $68.97 while gold traded up 1.5% at $2,645.80.
Silver traded up 1.6% to $29.890 on Friday, while copper rose 0.4% to $4.0925.
Euro zone
European shares were lower today. The eurozone's STOXX 600 dipped 0.99%, Germany's DAX fell 0.59% and France's CAC 40 declined 0.37%. Spain's IBEX 35 Index fell 0.10%, while London's FTSE 100 fell 0.25%.
Consumer confidence in the Eurozone declined by 0.8 points to a reading of -14.5 in December.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei 225 falling 0.29%, Hong Kong's Hang Seng Index falling 0.16%, China's Shanghai Composite Index declining 0.06% and India's BSE Sensex falling 1.49%.
Economics
<ul>
<li>The University of Michigan consumer sentiment rose to 74 in December, recording the highest level since April, and versus a reading of 71.8 in November.</li>
<li>U.S. personal income increased by 0.3% month-over-month in November compared to a revised 0.7% gain in October.</li>
<li>Personal spending increased by 0.4% to an annualized rate of $20.2 trillion in November.</li>
<li>The U.S. personal consumption expenditures price index rose 0.1% month-over-month in November down from 0.2% in each of the prior two months and compared to market estimates of 0.2%.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42616304/top-3-risk-off-stocks-that-may-collapse-this-month">Top 3 Risk Off Stocks That May Collapse This Month</a></li>
</ul>

Trading Ideas

Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher

U.S. stocks traded mostly higher this morning, with the Dow Jones index gaining around 100 points on Friday.
Following the market opening Friday, the Dow traded up 0.24% to 42,445.30 while the NASDAQ fell 0.13% to 19,347.54. The S&amp;P 500 also rose, gaining, 0.08% to 5,871.87.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a>
Leading and Lagging Sectors Real estate shares rose by 1.1% on Friday.
In trading on Friday, consumer staples shares fell by 0.4%.
Top Headline
Carnival Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) reported better-than-expected earnings for its fourth quarter on Friday.
The company posted quarterly earnings of 14 cents per share which beat the analyst consensus estimate of 8 cents per share. The company reported quarterly sales of $5.938 billion which beat the analyst consensus estimate of $5.932 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>My Size, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYSZ#NASDAQ">MYSZ</a>) shares shot up 349% to $6.11.</li>
<li>Shares of Helius Medical Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>)got a boost, surging 119% to $0.9901.</li>
<li>Taoping Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOP#NASDAQ">TAOP</a>) shares were also up, gaining 73% to $0.5490 after the company announced it received an additional 180 calendar days for compliance with the Nasdaq minimum bid price requirement.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares dropped 76% to $0.3895 as the company reported the pricing of $20.0 million follow on offering.</li>
<li>Shares of Galectin Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) were down 63% to $0.7600 after the company announced top-line results of its NAVIGATE clinical trial and confirmed belapectin did not achieve statistical significance.</li>
<li>PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) was down, falling 54% to $5.09.</li>
</ul>
Commodities In commodity news, oil traded down 1% to $68.73 while gold traded up 1.2% at $2,640.30.
Silver traded up 1.2% to $29.775 on Friday, while copper rose 0.4% to $4.0930.
Euro zone
European shares were lower today. The eurozone's STOXX 600 dipped 1.3%, Germany's DAX fell 0.9% and France's CAC 40 declined 0.7%. Spain's IBEX 35 Index fell 0.2%, while London's FTSE 100 fell 0.5%.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei 225 falling 0.29%, Hong Kong's Hang Seng Index falling 0.16%, China's Shanghai Composite Index declining 0.06% and India's BSE Sensex falling 1.49%.
Economics
<ul>
<li>The University of Michigan consumer sentiment rose to 74 in December, recording the highest level since April, and versus a reading of 71.8 in November.</li>
<li>U.S. personal income increased by 0.3% month-over-month in November compared to a revised 0.7% gain in October.</li>
<li>Personal spending increased by 0.4% to an annualized rate of $20.2 trillion in November.</li>
<li>The U.S. personal consumption expenditures price index rose 0.1% month-over-month in November down from 0.2% in each of the prior two months and compared to market estimates of 0.2%.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42616304/top-3-risk-off-stocks-that-may-collapse-this-month">Top 3 Risk Off Stocks That May Collapse This Month</a></li>
</ul>

MYSZ

PRFX

Dow Surges 100 Points, Carnival Earnings Top Views

On Friday, Galectin Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) released results from its global Phase2/3 NAVIGATE trial evaluating belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42614531/galectin-therapeutics-announces-top-line-results-of-navigate-clinical-trial-evaluating-belapectin-" rel="noreferrer noopener">and portal hypertension</a>.
355 patients were randomized. The primary endpoint was defined as the prevention of varices (abnormally dilated blood vessels that can occur in the veins, arteries, or lymphatic vessels), assessed as a composite clinical outcome that included subjects with any varices, those with intercurrent events, or those without an endoscopy or intercurrent events at 18 months.
Intercurrent events were defined as any liver-related complication, treatment discontinuation due to adverse events, use of non-selective beta-blockers.
In the intent-to-treat population (N=355), while the incidence of varices was 43.2% reduced in the belapectin 2 mg/kg dose group vs placebo, the composite endpoint did not reach statistical significance.
The per-protocol population was pre-defined as subjects who completed 18 months of therapy with upper endoscopy performed at baseline and 18 months.
In the PPP (n=290), the incidence of varices was reduced by 48.9% (compared to the targeted 52.5% reduction) in the belapectin 2 mg/kg dose group.
Additionally, the company is conducting the full NAVIGATE trial data analysis. It anticipates having additional data from approximately 50 patients who have completed 36 months of treatment with belapectin in early 2025.
Once available, Galectin will provide clinical updates and determine the next steps for belapectin development.
Price Action: GALT stock is down 59% at $0.80 at last check Friday. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42615125/why-is-bioengineered-human-tissue-focused-humacyte-stock-surging-on-friday" target="_blank" rel="noreferrer noopener">Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday?</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock.com

Health Care

Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday?

Galectin Therapeutics shares are trading lower after the company announced top-line results of its NAVIGATE clinical trial and confirmed belapectin did not achieve statistical significance.

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin; Says 'While there was a favorable trend for incidence of varices in the primary end point intent-to-treat population, belapectin did not achieve statistical significance'

<ul>
<li>Patient population for the NAVIGATE trial is based on non-invasive tests and clinical criteria utilizing latest treatment guidelines for portal hypertension in MASH cirrhosis</li>
<li>Blinded central review system can be effectively set-up for evaluation of esophagogastoduodenoscopy (EGD) in large multi-center trial of patients with MASH cirrhosis and portal hypertension, facilitating utilization of this outcome as a critical endpoint in portal hypertension trials</li>
<li>Approximately a third of patients with MASH cirrhosis and portal hypertension (PH) screened for the NAVIGATE trial had the incidental finding of varices on EGD, highlighting the need for screening EGDs in these patients</li>
<li>NAVIGATE trial readout on track for December 2024</li>
</ul>
NORCROSS, Ga., Nov. 18, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=9EfPtwQH7k-A18e4cqoz3QYAyz4BdEO_fl00GRDaJ9m3VNPJ_P7F9mYac7RAuk_Oi0x8a5ICMUvPVqgFMPlN6VwuT7YmH9OnttFBeQ0VaT4_7ZL7V8W5_kyv1cjlRVbI">Galectin Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>), the leading developer of therapeutics that target galectin proteins, today announced the presentation of three posters on the ongoing NAVIGATE trial in patients with MASH cirrhosis and portal hypertension at the American Association for the Study of Liver Diseases (AASLD)'s annual meeting 2024 Liver Meeting, being held November 15-19, 2024 in San Diego, California.

Galectin Therapeutics Presents 3 Abstracts At The American Association For The Study Of Liver Diseases 2024 Liver Meeting

HC Wainwright &amp; Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) with a Buy and maintains $11 price target.

Price Target

HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target

Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.12) by 50 percent. This is a 25 percent increase over losses of $(0.24) per share from the same period last year.

Galectin Therapeutics Q3 2024 GAAP EPS $(0.18) Misses $(0.12) Estimate

Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.16) by 25 percent. This is a 33.33 percent decrease over losses of $(0.15) per share from the same period last year.

Galectin Therapeutics Q2 EPS $(0.20) Misses $(0.16) Estimate

The Dow Jones index closed lower by over 50 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Bespoke Extracts</h3>
<ul>
<li>The Trade: Bespoke Extracts, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BSPK#OTC">BSPK</a>) CEO Michael Feinsod <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 3,000 shares at</a> an average price of $0.07. To acquire these shares, it cost around $210.</li>
<li>What's Happening: The company's stock jumped around 51% over the past six months.</li>
<li>What Bespoke Extracts Does: Bespoke Extracts Inc is focused on selling its proprietary line of specially-formulated, premium quality, hemp-derived CBD products.</li>
</ul>
<h3 class="wp-block-heading">Galectin Therapeutics</h3>
<ul>
<li>The Trade: Galectin Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) Director Kary Eldred <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 400 shares at</a> an average price of $2.39. To acquire these shares, it cost around $956.00.</li>
<li>What's Happening: On May 15, Galectin Therapeutics posted a wider-than-expected quarterly loss.</li>
<li>What Galectin Therapeutics Does: Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company.</li>
</ul>
<h3 class="wp-block-heading">RENN Fund</h3>
<ul>
<li>The Trade: RENN Fund, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCG#NYSE">RCG</a>) President and CEO Murray Stahl <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 1,499 shares</a> at an average price of $1.81. The insider spent around $2,713 to buy those shares. </li>
<li>What's Happening: RENN Fund shares rose around 7% over the past month.</li>
<li>What RENN Fund Does: RENN Fund Inc is active in the financial services domain.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39907046/best-buy-kroger-and-2-other-stocks-insiders-are-selling">Best Buy, Kroger And 2 Other Stocks Insiders Are Selling</a></li>
</ul>

Long Ideas

Penny Stocks

Insider Trades

Pre-Market Outlook

BSPK

Galectin Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying

Guidance

As Of March 31, 2024, Galectin Therapeutics Had $23.6M Of Cash And Cash Equivalents. Additionally, The Company Has $10M Remaining Available Under A $60M Line Of Credit Expected To Provide Cash Runway Into May 2025

Press Releases

Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference

Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update

Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial

Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update

Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress

Comments

Galectin Therapeutics

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL